-
Posted by
Two Blokes Jul 24 -
Filed in
Stock
-
11 views
Carlsmed's IPO debut is steady, with shares trading near the offering price, reflecting investor caution on its one-product, loss-making business model. Despite doubling sales and manageable cash burn, Carlsmed's valuation at 5–6x annualized sales appears reasonable given rapid revenue growth and a strong cash position. Key risks include heavy reliance on a single product, regulatory uncertainties, and competitive threats, making the investment thesis a high-risk, high-reward proposition.
